A5084826131- Multiple Myeloma Research and Treatments
- Single-cell and spatial transcriptomics
- Cancer therapeutics and mechanisms
- Peptidase Inhibition and Analysis
- CAR-T cell therapy research
- Monoclonal and Polyclonal Antibodies Research
- Genetics, Bioinformatics, and Biomedical Research
- Chronic Lymphocytic Leukemia Research
- Gene expression and cancer classification
- Cancer Genomics and Diagnostics
- Biofuel production and bioconversion
- Computational Physics and Python Applications
- Studies on Chitinases and Chitosanases
- Gene Regulatory Network Analysis
- Cancer Treatment and Pharmacology
- Protein Degradation and Inhibitors
- Enzyme Production and Characterization
- Scientific Computing and Data Management
- Water resources management and optimization
- Epigenetics and DNA Methylation
- Invertebrate Immune Response Mechanisms
- Ferroptosis and cancer prognosis
- Biosimilars and Bioanalytical Methods
- Explainable Artificial Intelligence (XAI)
- Iron oxide chemistry and applications
Janssen (United States)
2017-2023
Second Affiliated Hospital of Zhejiang University
2023
Utrecht University
2022
Tennessee Oncology
2022
Vrije Universiteit Amsterdam
2022
Sarah Cannon
2022
University Medical Center Utrecht
2022
Nanjing Normal University
2022
Boston University
2019-2022
The Affiliated Yongchuan Hospital of Chongqing Medical University
2021
G protein-coupled receptor, family C, group 5, member D (GPRC5D) is an orphan receptor expressed in malignant plasma cells. Talquetamab, a bispecific antibody against CD3 and GPRC5D, redirects T cells to mediate killing of GPRC5D-expressing myeloma cells.In phase 1 study, we evaluated talquetamab administered intravenously weekly or every other week (in doses from 0.5 180 μg per kilogram body weight) subcutaneously weekly, week, monthly (5 1600 kilogram) patients who had heavily pretreated...
Abstract Droplet-based microfluidic devices have become widely used to perform single-cell RNA sequencing (scRNA-seq). However, ambient present in the cell suspension can be aberrantly counted along with a cell’s native mRNA and result cross-contamination of transcripts between different populations. DecontX is novel Bayesian method estimate remove contamination individual cells. accurately predicts levels mouse-human mixture dataset removes aberrant expression marker genes PBMC datasets. We...
Summary Ibrutinib is highly active in treating mantle cell lymphoma ( MCL ), an aggressive B‐cell lymphoma. We pooled data from three ibrutinib studies to explore the impact of baseline patient characteristics on treatment response. Patients with relapsed/refractory n = 370) treated had objective response rate ORR ) 66% (20% complete response; 46% partial response); median duration DOR progression‐free survival PFS and overall OS were 18·6, 12·8 25·0 months, respectively. Univariate analyses...
Summary Daratumumab is a CD38‐targeting monoclonal antibody approved for intravenous (IV) infusion multiple myeloma (MM). We describe the Phase II PLEIADES study of subcutaneous formulation daratumumab (DARA SC) in combination with standard‐of‐care regimens: DARA SC plus bortezomib/lenalidomide/dexamethasone (D‐VRd) transplant‐eligible newly diagnosed MM (NDMM); bortezomib/melphalan/prednisone (D‐VMP) transplant‐ineligible NDMM; and lenalidomide/dexamethasone (D‐Rd) relapsed/refractory MM....
Abstract Single-cell RNA-seq (scRNA-seq) has emerged as a powerful technique to quantify gene expression in individual cells and elucidate the molecular cellular building blocks of complex tissues. We developed novel Bayesian hierarchical model called Cellular Latent Dirichlet Allocation (Celda) perform co-clustering genes into transcriptional modules subpopulations. Celda can probabilistic contribution each module, module cell population sample. In peripheral blood mononuclear dataset,...
8015 Background: G protein-coupled receptor family C group 5 member D (GPRC5D), which has limited expression in normal human tissue but is highly expressed on malignant plasma cells, a promising target for multiple myeloma (MM) immunotherapy. Talquetamab (JNJ-64407564) first-in-class, bispecific IgG4 antibody that binds to both GPRC5D and CD3 receptors, mediating T-cell–activated lysis of GPRC5D+ MM cells. Here we report updated results with additional patients (pts) longer follow-up from...
Large Language Model (LLMs) such as ChatGPT that exhibit generative AI capabilities are facing accelerated adoption and innovation. The increased presence of Generative (GAI) inevitably raises concerns about the risks safety associated with these models. This article provides an up-to-date survey recent trends in research GAI-LLMs from a computer scientist's perspective: specific technical. In this survey, we explore background motivation for identified harms context LLMs being language...
Abstract Mutational signatures are patterns of somatic alterations in the genome caused by carcinogenic exposures or aberrant cellular processes. To provide a comprehensive workflow for preprocessing, analysis, and visualization mutational signatures, we created Signature Comprehensive Analysis Toolkit (musicatk) package. musicatk enables users to select different schemas counting mutation types easily combine count tables from schemas. Multiple distinct methods available deconvolute predict...
Abstract In order to introduce the Tomato Spotted Wilt Virus ( TSWV ) resistance from Nicotiana alata into tabacum , a cytoplasmic male sterility CMS line of N. L. cv. gla .) S ‘K326’), was successfully crossed with . Despite high DNA content variability, F 1 hybrids could be classified in two subgroups, major one encompassing fertile morphologically similar their tobacco maternal parent but sensitive, and minor displaying sterile showing an intermediate phenotype resistant. elucidate...
To further improve the expression level of recombinant xylanase in Pichia pastoris, xynB gene, encoding mature peptide from Aspergillus niger NL-1, was designed and synthesized based on synonymous condon bias P. pastoris optimized G+C content. 155 nucleotides were changed, GC content decreased 57.7% to 43.6%. The synthetic inserted into pPICZaA then integrated GS115. activity reached 1414.7 U/mL, induced with 0.8% methanol after 14-day cultivation at a temperature 28oC shake flasks, which...
Abstract Single-cell RNA-seq (scRNA-seq) has emerged as a powerful technique to quantify gene expression in individual cells and elucidate the molecular cellular building blocks of complex tissues. We developed novel Bayesian hierarchical model called Cellular Latent Dirichlet Allocation (Celda) perform simultaneous co-clustering genes into transcriptional modules subpopulations. Celda can probabilistic contribution each module, module cell population, population sample. used identify...
ABSTRACT Droplet-based microfluidic devices have become widely used to perform single-cell RNA sequencing (scRNA-seq) and discover novel cellular heterogeneity in complex biological systems. However, ambient present the cell suspension can be incorporated into these droplets aberrantly counted along with a cell’s native mRNA. This results cross-contamination of transcripts between different populations potentially decrease precision downstream analyses. We developed hierarchical Bayesian...
G protein-coupled receptor family C group 5 member D (GPRC5D) has limited expression in healthy human tissue but is highly expressed malignant plasma cells, making it a promising target for immunotherapy approaches MM. Talquetamab (JNJ-64407564) first-in-class bispecific antibody that binds to both GPRC5D and CD3 receptors redirect T cells kill MM cells. Updated new results of talquetamab at the recommended phase 2 doses (RP2Ds) are reported (NCT03399799). Eligible patients had RRMM or were...
Background: G protein-coupled receptor family C group 5 member D (GPRC5D) is a promising therapeutic target for multiple myeloma (MM) immunotherapy. GPRC5D has limited expression in healthy human tissue but highly expressed on malignant plasma cells. Talquetamab (JNJ-64407564) first-in-class, x CD3 bispecific IgG4 antibody that induces T cell–activated lysis of GPRC5D+ MM. MonumenTAL-1 phase 1 trial evaluating the safety and preliminary efficacy talquetamab patients with relapsed/refractory...
8537 Background: Intravenous DARA (DARA IV) is approved for the treatment of MM. In Part 2 PAVO, SC, a concentrated, pre-mixed SC co-formulation and recombinant human hyaluronidase PH20 (rHuPH20), was well tolerated, with low infusion-related reaction (IRR) rate, showed consistent serum concentrations similar efficacy to IV in RRMM pts. PAVO 3, we evaluated safety pre- post-dose corticosteroid tapering during administration. Methods: pts ≥2 prior lines treatment, including proteasome...